Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

On Friday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $26.36 which represents a slight increase of $0.59 or 2.29% from the prior close of $25.77. The stock opened at $ and touched a ...

Pfizer on Tuesday said it does not expect the Trump administration to make major changes to vaccine policy next year even as ...

A community meeting organized by Easton council members to allow residents to hear more about a massive warehouse project ...

Pfizer stock has been weighed down lately, amid falling revenues and margins. The demand for the Covid-19 vaccine has taken a hit in recent years and the company has been looking to bridge the revenue ...

Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the ...

Pfizer on Tuesday forecast 2025 profit roughly in line with estimates, offering some relief to investors after the drugmaker ...

The efficacy data could help cushion Ibrance's losses of market share to Kisqali, a similar drug from Novartis.

Pfizer shares rallied after the drugmaker's 2025 guidance met Wall Street expectations, cheering shareholders as the ...

Pfizer shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 ...

Shares of the parent companies of pharmacy benefit managers fell Tuesday after President-elect Donald Trump and others ...